"Our mission is to provide our region with comprehensive eye care of the highest quality in an efficient and innovative manner and to continually improve that care through education and research. Hundreds of doctors and patients count on the Eye Institute to provide the very best in diagnosis, treatment, consultation, surgery, research, and education."

During the past decade, Black Hills Regional Eye Institute conducted 47 clinical trials. In the 10-year time frame, 47 clinical trials started and 28 clinical trials were completed, i.e. on average, 59.6% percent of trials that started reached the finish line to date. In the past 5 years, 21 clinical trials started and 21 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Black Hills Regional Eye Institute" #1 sponsor was "Hoffmann-La Roche" with 8 trials, followed by "Aerie Pharmaceuticals" with 4 trials sponsored, "Allergan" with 4 trials sponsored, "Kodiak Sciences Inc" with 4 trials sponsored and "Apellis Pharmaceuticals, Inc." with 4 trials sponsored. Other sponsors include 48 different institutions and companies that sponsored additional 47 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Black Hills Regional Eye Institute" #1 collaborator was "National Eye Institute (NEI)" with 3 trials as a collaborator, "Chugai Pharmaceutical" with 2 trials as a collaborator, "Genentech, Inc." with 2 trials as a collaborator, "Juvenile Diabetes Research Foundation" with 2 trials as a collaborator and "Otsuka Pharmaceutical Co., Ltd." with 2 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Black Hills Regional Eye Institute" are "Diabetic Macular Edema" (10 trials), "Macular Degeneration" (9 trials), "Geographic Atrophy" (7 trials), "Macular Edema" (5 trials) and "Age-Related Macular Degeneration" (3 trials). Many other conditions were trialed in "Black Hills Regional Eye Institute" in a lesser frequency.

Most popular intervention types in "Black Hills Regional Eye Institute" are "Drug" (67 trials), "Other" (13 trials), "Procedure" (6 trials), "Biological" (3 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (13 trials), "Aflibercept" (11 trials), "Placebo" (7 trials), "Ranibizumab" (7 trials) and "Faricimab" (6 trials). Other intervention names were less common.

The vast majority of trials in "Black Hills Regional Eye Institute" are 75 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Black Hills Regional Eye Institute". undefined are not yet recruiting, 2 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 51 completed trials in Black Hills Regional Eye Institute, undefined suspended trials, and 12 terminated clinical trials to date.

Out of the total trials that were conducted in Black Hills Regional Eye Institute, 7 "Phase 1" clinical trials were conducted, 32 "Phase 2" clinical trials and 34 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".